Skip to main content
PMC home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1993 Mar 1;90(5):1839–1842. doi: 10.1073/pnas.90.5.1839

Three inhibitors of type 1 human immunodeficiency virus long terminal repeat-directed gene expression and virus replication.

C J Li 1, L J Zhang 1, B J Dezube 1, C S Crumpacker 1, A B Pardee 1
PMCID: PMC45975  PMID: 8446597

Abstract

Transcription of type 1 human immunodeficiency virus (HIV-1) provirus is governed by the viral long terminal repeat (LTR). Drugs can block HIV-1 replication by inhibiting activity of its LTR. We report that topotecan, beta-lapachone, and curcumin are potent and selective inhibitors of HIV-1 LTR-directed gene expression, at concentrations that have minor effects on cells. At these concentrations, each drug inhibited p24 antigen production in cells either acutely or chronically infected with HIV-1. Their target is transcriptional function of the LTR.

Full text

PDF
1839

Images in this article

1840Fig. 1
on p.1840

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ammon H. P., Wahl M. A. Pharmacology of Curcuma longa. Planta Med. 1991 Feb;57(1):1–7. doi: 10.1055/s-2006-960004. [DOI] [PubMed] [Google Scholar]
  2. Boothman D. A., Pardee A. B. Inhibition of radiation-induced neoplastic transformation by beta-lapachone. Proc Natl Acad Sci U S A. 1989 Jul;86(13):4963–4967. doi: 10.1073/pnas.86.13.4963. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Brenner D. A., O'Hara M., Angel P., Chojkier M., Karin M. Prolonged activation of jun and collagenase genes by tumour necrosis factor-alpha. Nature. 1989 Feb 16;337(6208):661–663. doi: 10.1038/337661a0. [DOI] [PubMed] [Google Scholar]
  4. Cullen B. R., Greene W. C. Regulatory pathways governing HIV-1 replication. Cell. 1989 Aug 11;58(3):423–426. doi: 10.1016/0092-8674(89)90420-0. [DOI] [PubMed] [Google Scholar]
  5. Fazely F., Dezube B. J., Allen-Ryan J., Pardee A. B., Ruprecht R. M. Pentoxifylline (Trental) decreases the replication of the human immunodeficiency virus type 1 in human peripheral blood mononuclear cells and in cultured T cells. Blood. 1991 Apr 15;77(8):1653–1656. [PubMed] [Google Scholar]
  6. Folks T. M., Clouse K. A., Justement J., Rabson A., Duh E., Kehrl J. H., Fauci A. S. Tumor necrosis factor alpha induces expression of human immunodeficiency virus in a chronically infected T-cell clone. Proc Natl Acad Sci U S A. 1989 Apr;86(7):2365–2368. doi: 10.1073/pnas.86.7.2365. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Gonçalves A. M., Vasconcellos M. E., Docampo R., Cruz F. S., de Souza W., Leon W. Evaluation of the toxicity of 3-allyl-beta-lapachone against Trypanosoma cruzi bloodstream forms. Mol Biochem Parasitol. 1980 Jun;1(3):167–176. doi: 10.1016/0166-6851(80)90015-8. [DOI] [PubMed] [Google Scholar]
  8. Griffin G. E., Leung K., Folks T. M., Kunkel S., Nabel G. J. Activation of HIV gene expression during monocyte differentiation by induction of NF-kappa B. Nature. 1989 May 4;339(6219):70–73. doi: 10.1038/339070a0. [DOI] [PubMed] [Google Scholar]
  9. Herbomel P., Bourachot B., Yaniv M. Two distinct enhancers with different cell specificities coexist in the regulatory region of polyoma. Cell. 1984 Dec;39(3 Pt 2):653–662. doi: 10.1016/0092-8674(84)90472-0. [DOI] [PubMed] [Google Scholar]
  10. Hsu M. C., Schutt A. D., Holly M., Slice L. W., Sherman M. I., Richman D. D., Potash M. J., Volsky D. J. Inhibition of HIV replication in acute and chronic infections in vitro by a Tat antagonist. Science. 1991 Dec 20;254(5039):1799–1802. doi: 10.1126/science.1763331. [DOI] [PubMed] [Google Scholar]
  11. Kingsbury W. D., Boehm J. C., Jakas D. R., Holden K. G., Hecht S. M., Gallagher G., Caranfa M. J., McCabe F. L., Faucette L. F., Johnson R. K. Synthesis of water-soluble (aminoalkyl)camptothecin analogues: inhibition of topoisomerase I and antitumor activity. J Med Chem. 1991 Jan;34(1):98–107. doi: 10.1021/jm00105a017. [DOI] [PubMed] [Google Scholar]
  12. Lähdevirta J., Maury C. P., Teppo A. M., Repo H. Elevated levels of circulating cachectin/tumor necrosis factor in patients with acquired immunodeficiency syndrome. Am J Med. 1988 Sep;85(3):289–291. doi: 10.1016/0002-9343(88)90576-1. [DOI] [PubMed] [Google Scholar]
  13. Maeda H. Neocarzinostatin in cancer chemotherapy (review). Anticancer Res. 1981;1(3):175–186. [PubMed] [Google Scholar]
  14. Mitsuya H., Yarchoan R., Broder S. Molecular targets for AIDS therapy. Science. 1990 Sep 28;249(4976):1533–1544. doi: 10.1126/science.1699273. [DOI] [PubMed] [Google Scholar]
  15. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983 Dec 16;65(1-2):55–63. doi: 10.1016/0022-1759(83)90303-4. [DOI] [PubMed] [Google Scholar]
  16. Nabel G. J., Rice S. A., Knipe D. M., Baltimore D. Alternative mechanisms for activation of human immunodeficiency virus enhancer in T cells. Science. 1988 Mar 11;239(4845):1299–1302. doi: 10.1126/science.2830675. [DOI] [PubMed] [Google Scholar]
  17. Priel E., Showalter S. D., Blair D. G. Inhibition of human immunodeficiency virus (HIV-1) replication in vitro by noncytotoxic doses of camptothecin, a topoisomerase I inhibitor. AIDS Res Hum Retroviruses. 1991 Jan;7(1):65–72. doi: 10.1089/aid.1991.7.65. [DOI] [PubMed] [Google Scholar]
  18. Priel E., Showalter S. D., Roberts M., Oroszlan S., Segal S., Aboud M., Blair D. G. Topoisomerase I activity associated with human immunodeficiency virus (HIV) particles and equine infectious anemia virus core. EMBO J. 1990 Dec;9(12):4167–4172. doi: 10.1002/j.1460-2075.1990.tb07640.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Roederer M., Staal F. J., Raju P. A., Ela S. W., Herzenberg L. A., Herzenberg L. A. Cytokine-stimulated human immunodeficiency virus replication is inhibited by N-acetyl-L-cysteine. Proc Natl Acad Sci U S A. 1990 Jun;87(12):4884–4888. doi: 10.1073/pnas.87.12.4884. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Rowinsky E. K., Grochow L. B., Hendricks C. B., Ettinger D. S., Forastiere A. A., Hurowitz L. A., McGuire W. P., Sartorius S. E., Lubejko B. G., Kaufmann S. H. Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. J Clin Oncol. 1992 Apr;10(4):647–656. doi: 10.1200/JCO.1992.10.4.647. [DOI] [PubMed] [Google Scholar]
  21. Satoskar R. R., Shah S. J., Shenoy S. G. Evaluation of anti-inflammatory property of curcumin (diferuloyl methane) in patients with postoperative inflammation. Int J Clin Pharmacol Ther Toxicol. 1986 Dec;24(12):651–654. [PubMed] [Google Scholar]
  22. Schaffner-Sabba K., Schmidt-Ruppin K. H., Wehrli W., Schuerch A. R., Wasley J. W. beta-Lapachone: synthesis of derivatives and activities in tumor models. J Med Chem. 1984 Aug;27(8):990–994. doi: 10.1021/jm00374a010. [DOI] [PubMed] [Google Scholar]
  23. Schuerch A. R., Wehrli W. beta-Lapachone, an inhibitor of oncornavirus reverse transcriptase and eukaryotic DNA polymerase-alpha. Inhibitory effect, thiol dependence and specificity. Eur J Biochem. 1978 Mar;84(1):197–205. doi: 10.1111/j.1432-1033.1978.tb12157.x. [DOI] [PubMed] [Google Scholar]
  24. Shankar T. N., Shantha N. V., Ramesh H. P., Murthy I. A., Murthy V. S. Toxicity studies on turmeric (Curcuma longa): acute toxicity studies in rats, guineapigs & monkeys. Indian J Exp Biol. 1980 Jan;18(1):73–75. [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES